This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fung-Tomc, J. C.
Right arrow Articles by Bonner, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fung-Tomc, J. C.
Right arrow Articles by Bonner, D. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2002, p. 971-976, Vol. 46, No. 4
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.4.971-976.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

In Vitro and In Vivo Activities of a Novel Cephalosporin, BMS-247243, against Methicillin-Resistant and -Susceptible Staphylococci

Joan C. Fung-Tomc,* Junius Clark, Beatrice Minassian, Michael Pucci, Yuan-Hwang Tsai, Elizabeth Gradelski, Lucinda Lamb, Ivette Medina, Elizabeth Huczko, Benjamin Kolek, Susan Chaniewski, Cheryl Ferraro, Thomas Washo, and Daniel P. Bonner

Department of Microbiology, Bristol-Myers Squibb Co., Wallingford, Connecticut 06492

Received 23 March 2001/ Returned for modification 27 October 2001/ Accepted 2 January 2002

The recent emergence of methicillin-resistant Staphylococcus aureus (MRSA) with decreased susceptibility to vancomycin has intensified the search for alternative therapies for the treatment of infections caused by this organism. One approach has been to identify a ß-lactam with improved affinity for PBP 2a, the target enzyme responsible for methicillin resistance in staphylococci. BMS-247243 is such a candidate, with MICs that inhibit 90% of isolates tested (MIC90s) of 4, 2, and 8 µg/ml for methicillin-resistant strains of S. aureus, S. epidermidis, and S. haemolyticus, respectively, as determined on plates with Mueller-Hinton agar and 2% NaCl. The BMS-247243 MICs for MRSA were minimally affected by the susceptibility testing conditions (inoculum size, prolonged incubation, addition of salt to the test medium) or by staphylococcal ß-lactamases. BMS-247243 MIC90s for methicillin-susceptible staphylococcal species ranged from <=0.25 to 1 µg/ml. The BMS-247243 MIC90 for ß-lactamase-producing S. aureus strains was fourfold higher than that for ß-lactamase-nonproducing strains. BMS-247243 is hydrolyzed by staphylococccal ß-lactamases at 4.5 to 26.2% of the rates measured for cephaloridine. The affinity of BMS-247243 for PBP 2a was >100-fold better than that of methicillin or cefotaxime. BMS-247243 is bactericidal for MRSA, killing the bacteria twice as fast as vancomycin. These in vitro activities of BMS-247243 correlated with its in vivo efficacy against infections in animals, including the neutropenic murine thigh and rabbit endocarditis models involving MRSA strains. In conclusion, BMS-247243 has in vitro and in vivo activities against methicillin-resistant staphylococci and thus may prove to be useful in the treatment of infections caused by these multidrug-resistant organisms.

* Corresponding author. Mailing address: Department of Microbiology-104, Bristol-Myers Squibb Co., 5 Research Pkwy., Wallingford, CT 06492. Phone: (203) 677-6370. Fax: (203) 677-6771. E-mail: fungtomj{at}bms.com.

Antimicrobial Agents and Chemotherapy, April 2002, p. 971-976, Vol. 46, No. 4
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.4.971-976.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Goldstein, F., Perutka, J., Cuirolo, A., Plata, K., Faccone, D., Morris, J., Sournia, A., Kitzis, M. D., Ly, A., Archer, G., Rosato, A. E. (2007). Identification and Phenotypic Characterization of a {beta}-Lactam-Dependent, Methicillin-Resistant Staphylococcus aureus Strain. Antimicrob. Agents Chemother. 51: 2514-2522 [Abstract] [Full Text]  
  • Ueda, Y., Kanazawa, K., Eguchi, K., Takemoto, K., Eriguchi, Y., Sunagawa, M. (2005). In Vitro and In Vivo Antibacterial Activities of SM-216601, a New Broad-Spectrum Parenteral Carbapenem. Antimicrob. Agents Chemother. 49: 4185-4196 [Abstract] [Full Text]  
  • Cerca, N., Martins, S., Cerca, F., Jefferson, K. K., Pier, G. B., Oliveira, R., Azeredo, J. (2005). Comparative assessment of antibiotic susceptibility of coagulase-negative staphylococci in biofilm versus planktonic culture as assessed by bacterial enumeration or rapid XTT colorimetry. J Antimicrob Chemother 56: 331-336 [Abstract] [Full Text]  
  • Kotani, T., Nagai, D., Asahi, K., Suzuki, H., Yamao, F., Kataoka, N., Yagura, T. (2005). Antibacterial Properties of Some Cyclic Organobismuth(III) Compounds. Antimicrob. Agents Chemother. 49: 2729-2734 [Abstract] [Full Text]  
  • Chambers, H. F. (2005). Evaluation of Ceftobiprole in a Rabbit Model of Aortic Valve Endocarditis Due to Methicillin-Resistant and Vancomycin-Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 884-888 [Abstract] [Full Text]  
  • Huang, V., Brown, W. J., Rybak, M. J. (2004). In Vitro Activities of a Novel Cephalosporin, CB-181963 (CAB-175), against Methicillin-Susceptible or -Resistant Staphylococcus aureus and Glycopeptide-Intermediate Susceptible Staphylococci. Antimicrob. Agents Chemother. 48: 2719-2723 [Abstract] [Full Text]  
  • Christiansen, K. J., Bell, J. M., Turnidge, J. D., Jones, R. N. (2004). Antimicrobial Activities of Garenoxacin (BMS 284756) against Asia-Pacific Region Clinical Isolates from the SENTRY Program, 1999 to 2001. Antimicrob. Agents Chemother. 48: 2049-2055 [Abstract] [Full Text]  
  • Katayama, Y., Zhang, H.-Z., Chambers, H. F. (2004). PBP 2a Mutations Producing Very-High-Level Resistance to Beta-Lactams. Antimicrob. Agents Chemother. 48: 453-459 [Abstract] [Full Text]  
  • Ueda, Y., Sunagawa, M. (2003). In Vitro and In Vivo Activities of Novel 2-(Thiazol-2-ylthio)-1{beta}-Methylcarbapenems with Potent Activities against Multiresistant Gram-Positive Bacteria. Antimicrob. Agents Chemother. 47: 2471-2480 [Abstract] [Full Text]  
  • Tsuji, M., Takema, M., Miwa, H., Shimada, J., Kuwahara, S. (2003). In Vivo Antibacterial Activity of S-3578, a New Broad-Spectrum Cephalosporin: Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa Experimental Infection Models. Antimicrob. Agents Chemother. 47: 2507-2512 [Abstract] [Full Text]  
  • Fujimura, T., Yamano, Y., Yoshida, I., Shimada, J., Kuwahara, S. (2003). In Vitro Activity of S-3578, a New Broad-Spectrum Cephalosporin Active against Methicillin-Resistant Staphylococci. Antimicrob. Agents Chemother. 47: 923-931 [Abstract] [Full Text]  
  • Clark, J., Fung-Tomc, J. C., Minassian, B., Tsai, Y.-H., Yang, H., Huczko, E., Kolek, B., Chaniewski, S., Ferraro, C., Drain, R., Gradelski, E., Bonner, D. P. (2002). In Vitro and In Vivo Activities of a Novel Cephalosporin, BMS-247243, against Organisms other than Staphylococci. Antimicrob. Agents Chemother. 46: 1108-1111 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»